Houston, TX, United States of America

Naveen Sharma

This inventor holds 1 USPTO granted patent. Top assignee: The University of Texas System. Active years: 2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Naveen Sharma. Retrieved from https://idiyas.com/inventor/naveen-sharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Naveen Sharma in Cancer Treatment

Introduction

Naveen Sharma is a notable inventor based in Houston, Texas, recognized for his contributions to cancer treatment through innovative antibody technologies. His work focuses on developing therapies that can significantly impact patient outcomes in oncology.

Latest Patents

Sharma holds a patent for a LILRB4-binding antibody and methods of use thereof. This patent outlines the use of LILRB4-binding antibodies in treating cancer, either alone or in combination with other therapies. Additionally, it includes recombinant polypeptides that comprise the CDRs of these antibodies, showcasing a novel approach to cancer treatment.

Career Highlights

Naveen Sharma is affiliated with the University of Texas System, where he continues to advance his research and development efforts in the field of cancer therapeutics. His work is characterized by a commitment to improving treatment options for patients facing cancer.

Collaborations

Sharma collaborates with esteemed colleagues, including James P. Allison, who is also a prominent figure in cancer research. Their combined expertise contributes to the advancement of innovative therapies in the medical field.

Conclusion

Naveen Sharma's work exemplifies the intersection of innovation and healthcare, particularly in the realm of cancer treatment. His contributions through patents and collaborations are paving the way for new therapeutic strategies that could benefit many patients.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…